Literature DB >> 19042044

Statin therapy shortens QTc, QTcd, and improves cardiac function in patients with chronic heart failure.

Rui-qin Xie, Wei Cui, Fan Liu, Chao Yang, Wei-na Pei, Jing-chao Lu.   

Abstract

Although some data suggest that statins can improve cardiac mechanical function in some patients with chronic heart failure (CHF), the effects of long-term statin therapy on cardiac electrical instability remain unclear. We performed a randomized perspective analysis of the effects of 10 mg/d (statin group 1, n=40), 20 mg/d (statin group 2, n=38) of atorvastatin and controls (control group, n=41) on corrected QT intervals (QTc), corrected QT dispersion (QTcd) and cardiac function in patients with CHF secondary to coronary artery disease (CAD) for one year. At 6 and 12 months, the statin groups displayed lower QTc and QTcd compared with controls. The changes were becoming more distinct in statin group 2, (P<0.05). In statin groups, the changes of QTc and QTcd were independent of changes of plasma low-density lipoprotein cholesterol and total cholesterol levels, and the decrease of QTcd was correlated with the increase of LVEF within 12 months. Atorvastatin shortens QTc, QTcd and improves cardiac function, and might thereby be parts of the mechanisms which atorvastatin benefited CHF patients secondary to CAD. Copyright 2008 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19042044     DOI: 10.1016/j.ijcard.2008.11.030

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  12 in total

Review 1.  Statin therapy in heart failure: for good, for bad, or indifferent?

Authors:  Luisa De Gennaro; Natale Daniele Brunetti; Michele Correale; Francesco Buquicchio; Pasquale Caldarola; Matteo Di Biase
Journal:  Curr Atheroscler Rep       Date:  2014-01       Impact factor: 5.113

2.  Facts, fancies and follies of drug-induced QT/QTc interval shortening.

Authors:  Marek Malik
Journal:  Br J Pharmacol       Date:  2010-01       Impact factor: 8.739

Review 3.  Left ventricular ejection fraction as therapeutic target: is it the ideal marker?

Authors:  V Katsi; G Georgiopoulos; A Laina; E Koutli; J Parissis; C Tsioufis; P Nihoyannopoulos; D Tousoulis
Journal:  Heart Fail Rev       Date:  2017-11       Impact factor: 4.214

4.  Fluvastatin inhibits Rab5-mediated IKs internalization caused by chronic Ca2+-dependent PKC activation.

Authors:  Xiaorong Xu Parks; Elsa Ronzier; Jin O-Uchi; Coeli M Lopes
Journal:  J Mol Cell Cardiol       Date:  2019-03-18       Impact factor: 5.000

5.  Effect of atorvastatin on testosterone levels.

Authors:  Muhammad Ismail Shawish; Bahador Bagheri; Vijaya M Musini; Stephen P Adams; James M Wright
Journal:  Cochrane Database Syst Rev       Date:  2021-01-22

6.  Effect of atorvastatin in patients with chronic heart failure - insights from randomized clinical trials.

Authors:  Minwen Xu; Gaohui Yuan; Fanping Wei
Journal:  Arch Med Sci       Date:  2010-12-29       Impact factor: 3.318

Review 7.  Statins in heart failure: do we need another trial?

Authors:  Kwadwo Osei Bonsu; Amudha Kadirvelu; Daniel Diamond Reidpath
Journal:  Vasc Health Risk Manag       Date:  2013-06-17

8.  Nebivolol therapy improves QTc and QTcd parameters in heart failure patients.

Authors:  S M Aksoy; S Cay; G Cagirci; N Sen
Journal:  Cardiovasc J Afr       Date:  2012-05       Impact factor: 1.167

9.  No benefits of statins for sudden cardiac death prevention in patients with heart failure and reduced ejection fraction: A meta-analysis of randomized controlled trials.

Authors:  Muaamar Al-Gobari; Hai-Ha Le; Mor Fall; François Gueyffier; Bernard Burnand
Journal:  PLoS One       Date:  2017-02-06       Impact factor: 3.240

10.  Improvement of cardiac function and reversal of gap junction remodeling by Neuregulin-1β in volume-overloaded rats with heart failure.

Authors:  Xue-Hui Wang; Xiao-Zhen Zhuo; Ya-Juan Ni; Min Gong; Ting-Zhong Wang; Qun Lu; Ai-Qun Ma
Journal:  J Geriatr Cardiol       Date:  2012-06       Impact factor: 3.327

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.